Inhibikase Therapeutics Inc
NASDAQ:IKT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its Industry Average (19.1), the stock would be worth $-6.92 (472% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -5.1 | $1.86 |
0%
|
| Industry Average | 19.1 | $-6.92 |
-472%
|
| Country Average | 22.9 | $-8.28 |
-545%
|
Forward P/E
Today’s price vs future net income
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Inhibikase Therapeutics Inc
NASDAQ:IKT
|
244.9m USD | -5.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.5B USD | 86.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.2B USD | 23.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
159.9B USD | 18.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.5B USD | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
72.5B USD | 16.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
40.6B EUR | 36.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.6B AUD | 29.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.3 |
| Median | 22.9 |
| 70th Percentile | 33.2 |
| Max | 1 826 183.3 |
Other Multiples
Inhibikase Therapeutics Inc
Glance View
Inhibikase Therapeutics, Inc. provides infectious disease treatments. The company is headquartered in Atlanta, Georgia and currently employs 6 full-time employees. The company went IPO on 2020-12-23. The firm is focused on developing therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The firm's product candidates include IkT-148009, IkT-001pro, and IKT-01427. Its lead product candidate, IkT-148009 is for the treatment of PD and for the treatment of gastrointestinal (GI), complications that arise as early symptoms of PD in patients. The Company’s kT-148009 is a brain penetrant c-Abl protein kinase inhibitor that halts disease progression and reverses functional loss in the brain and reverses neurological dysfunction in the GI tract. Its product candidate IkT-001Pro, is a prodrug of the anticancer agent Imatinibm, and used as a treatment for chronic myelogenous leukemia (CML). IkT-01427 is an oral, brain-penetrant medication , designed to block the entry of the JC virus into the cell, thereby preventing the virus’ ability to replicate in the body.
